NCT Number: NCT00002069
A Study of DTC in Patients With AIDS and AIDS Related Complex
To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Univ of Arizona / Arizona Cancer Ctr, Tucson, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Concurrent Medication:
Allowed:
- Zidovudine (AZT).
Exclusion criteria
Co-existing Condition:
Patients with the following are excluded:
- Active opportunistic infection or progressive Kaposi's sarcoma (KS).
- Dementia.
- Lymphoma.
Concurrent Medication:
Excluded within 3 weeks of study entry:
- Other experimental AIDS therapy.
Patients with the following are excluded:
- Active opportunistic infection or progressive Kaposi's sarcoma (KS).
Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Merieux Institute
Industry
Registry information
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
NCT00000810
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Stanford, California, United States
View Trial DetailsA Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
NCT00000842
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsA Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
NCT00000782
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Palo Alto, California, United States
View Trial DetailsComparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection
NCT00000739
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Long Beach, California, United States
View Trial Details